Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Abstract Background Data on the treatment of patients with hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfection remains limited. A comprehensive analysis was performed to evaluate the efficacy and safety of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir(r) ± dasabuvir (DSV) ± ribavi...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-01-01
|
| Series: | Virology Journal |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12985-018-1114-4 |
| _version_ | 1819032924570255360 |
|---|---|
| author | Jingjing Wu Peng Huang Haozhi Fan Ting Tian Xueshan Xia Zuqiang Fu Yan Wang Xiangyu Ye Ming Yue Yun Zhang |
| author_facet | Jingjing Wu Peng Huang Haozhi Fan Ting Tian Xueshan Xia Zuqiang Fu Yan Wang Xiangyu Ye Ming Yue Yun Zhang |
| author_sort | Jingjing Wu |
| collection | DOAJ |
| description | Abstract Background Data on the treatment of patients with hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfection remains limited. A comprehensive analysis was performed to evaluate the efficacy and safety of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir(r) ± dasabuvir (DSV) ± ribavirin (RBV) for treatment in HCV/HIV coinfected patients. Methods We systematically searched and included studies that enrolled patients with HIV/HCV coinfection using the OBV/PTV/r ± DSV ± RBV regimens and reported sustained virological response after 12 weeks (SVR12) end-of-treatment. Heterogeneity of results was assessed and pooled SVR rates were computed with 95% confidence intervals (95%CI). Subgroup analysis and assessment of publication bias through Egger’s test were further performed. Results Ten studies containing 1358 coinfected patients were included in this study. The pooled estimate of SVR12 was 96.3% (95%CI: 95.1–97.4). Subgroup analysis showed that pooled SVR12 rate was 96.2% (95% CI: 94.8–97.4) for patients with genotype (GT) 1 and 98.8% (95% CI: 95.1–100.0) for those with GT4. The SVR12 rates for the treatment-naïve (TN) and treatment-experienced (TE) patients were 96.8% (95% CI, 94.8–98.5) and 98.9% (95% CI, 96.4–100.0), respectively. Pooled SVR12 rate was 97.8(95%CI: 94.6–99.8) for patients with cirrhosis and 96.7% (95%CI: 95.3–97.8) without cirrhosis. The pooled incidence of any adverse events (AEs) and serious adverse events (SAEs) was 73.9% (95%CI: 38.1–97.6) and 2.7% (95%CI: 0.0–9.5). Publication bias did not exist in this study. Conclusions The comprehensive analysis showed high efficacy for the OBV/PTV/r ± DSV ± RBV regimen in patients coinfected with HIV and HCV, regardless of genotypes, history of treatment and the presence or absence of cirrhosis. |
| first_indexed | 2024-12-21T07:09:40Z |
| format | Article |
| id | doaj.art-4cffcb73199e4b39b66123dcb59b5b98 |
| institution | Directory Open Access Journal |
| issn | 1743-422X |
| language | English |
| last_indexed | 2024-12-21T07:09:40Z |
| publishDate | 2019-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Virology Journal |
| spelling | doaj.art-4cffcb73199e4b39b66123dcb59b5b982022-12-21T19:12:00ZengBMCVirology Journal1743-422X2019-01-0116111010.1186/s12985-018-1114-4Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysisJingjing Wu0Peng Huang1Haozhi Fan2Ting Tian3Xueshan Xia4Zuqiang Fu5Yan Wang6Xiangyu Ye7Ming Yue8Yun Zhang9Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityDepartment of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityDepartment of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityDepartment of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityFaculty of Life Science and Technology, Kunming University of Science and TechnologyDepartment of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityDepartment of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityDepartment of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityDepartment of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityAbstract Background Data on the treatment of patients with hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfection remains limited. A comprehensive analysis was performed to evaluate the efficacy and safety of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir(r) ± dasabuvir (DSV) ± ribavirin (RBV) for treatment in HCV/HIV coinfected patients. Methods We systematically searched and included studies that enrolled patients with HIV/HCV coinfection using the OBV/PTV/r ± DSV ± RBV regimens and reported sustained virological response after 12 weeks (SVR12) end-of-treatment. Heterogeneity of results was assessed and pooled SVR rates were computed with 95% confidence intervals (95%CI). Subgroup analysis and assessment of publication bias through Egger’s test were further performed. Results Ten studies containing 1358 coinfected patients were included in this study. The pooled estimate of SVR12 was 96.3% (95%CI: 95.1–97.4). Subgroup analysis showed that pooled SVR12 rate was 96.2% (95% CI: 94.8–97.4) for patients with genotype (GT) 1 and 98.8% (95% CI: 95.1–100.0) for those with GT4. The SVR12 rates for the treatment-naïve (TN) and treatment-experienced (TE) patients were 96.8% (95% CI, 94.8–98.5) and 98.9% (95% CI, 96.4–100.0), respectively. Pooled SVR12 rate was 97.8(95%CI: 94.6–99.8) for patients with cirrhosis and 96.7% (95%CI: 95.3–97.8) without cirrhosis. The pooled incidence of any adverse events (AEs) and serious adverse events (SAEs) was 73.9% (95%CI: 38.1–97.6) and 2.7% (95%CI: 0.0–9.5). Publication bias did not exist in this study. Conclusions The comprehensive analysis showed high efficacy for the OBV/PTV/r ± DSV ± RBV regimen in patients coinfected with HIV and HCV, regardless of genotypes, history of treatment and the presence or absence of cirrhosis.http://link.springer.com/article/10.1186/s12985-018-1114-43DAAHCVHIVSVR12 |
| spellingShingle | Jingjing Wu Peng Huang Haozhi Fan Ting Tian Xueshan Xia Zuqiang Fu Yan Wang Xiangyu Ye Ming Yue Yun Zhang Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis Virology Journal 3DAA HCV HIV SVR12 |
| title | Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis |
| title_full | Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis |
| title_fullStr | Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis |
| title_full_unstemmed | Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis |
| title_short | Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis |
| title_sort | effectiveness of ombitasvir paritaprevir ritonavir dasabuvir for hcv in hiv hcv coinfected subjects a comprehensive analysis |
| topic | 3DAA HCV HIV SVR12 |
| url | http://link.springer.com/article/10.1186/s12985-018-1114-4 |
| work_keys_str_mv | AT jingjingwu effectivenessofombitasvirparitaprevirritonavirdasabuvirforhcvinhivhcvcoinfectedsubjectsacomprehensiveanalysis AT penghuang effectivenessofombitasvirparitaprevirritonavirdasabuvirforhcvinhivhcvcoinfectedsubjectsacomprehensiveanalysis AT haozhifan effectivenessofombitasvirparitaprevirritonavirdasabuvirforhcvinhivhcvcoinfectedsubjectsacomprehensiveanalysis AT tingtian effectivenessofombitasvirparitaprevirritonavirdasabuvirforhcvinhivhcvcoinfectedsubjectsacomprehensiveanalysis AT xueshanxia effectivenessofombitasvirparitaprevirritonavirdasabuvirforhcvinhivhcvcoinfectedsubjectsacomprehensiveanalysis AT zuqiangfu effectivenessofombitasvirparitaprevirritonavirdasabuvirforhcvinhivhcvcoinfectedsubjectsacomprehensiveanalysis AT yanwang effectivenessofombitasvirparitaprevirritonavirdasabuvirforhcvinhivhcvcoinfectedsubjectsacomprehensiveanalysis AT xiangyuye effectivenessofombitasvirparitaprevirritonavirdasabuvirforhcvinhivhcvcoinfectedsubjectsacomprehensiveanalysis AT mingyue effectivenessofombitasvirparitaprevirritonavirdasabuvirforhcvinhivhcvcoinfectedsubjectsacomprehensiveanalysis AT yunzhang effectivenessofombitasvirparitaprevirritonavirdasabuvirforhcvinhivhcvcoinfectedsubjectsacomprehensiveanalysis |